Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte's Web, Shock Top, Montauk Brewing, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point, Alpine, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Cruisies, Atwater Brewery, Hi-ball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner's High Brewing Company, SweetWater Brewing Company, Terrapin brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.…
Tilray Has More Cash Than Debt and 71% Growth in Europe. Is This Cannabis Stock a Buy?
Tilray Brands (NASDAQ: TLRY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 3,595 employees.
The shares were at 1.890 USD on 20 November 2026, down 85.3% over 52 weeks. Its 52-week range is 1.870 USD to 15.70 USD: the price is 88.0% below the high and 1.1% above the low.
Its market capitalisation is 279.32M USD.
Tilray Brands reports return on equity of -7.5%, an operating margin of -6.0% and revenue up 22.7% year over year.
Its debt exceeds its cash by 153.92M USD, a debt-to-equity ratio of 0.25. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 9 analysts cover the stock; their mean price target of 5.722 USD is 202.8% above the current price. The next earnings report is expected on 7 January 2027.